Lactobacillus acidophilus Metabolizes Dietary Plant Glucosides and Externalizes Their Bioactive Phytochemicals

Theilmann, Mia Christine; Goh, Yong Jun; Nielsen, Kristian Fog; Klaenhammer, Todd R.; Barrangou, Rodolphe; Abou Hachem, Maher; Martens, Eric; McFall-Ngai, Margaret J.

Published in:
mBio (Online)

Link to article, DOI:
10.1128/mBio.01421-17

Publication date:
2017

Document Version
Publisher's PDF, also known as Version of record

Link back to DTU Orbit

Citation (APA):
Theilmann, M. C., Goh, Y. J., Nielsen, K. F., Klaenhammer, T. R., Barrangou, R., Abou Hachem, M., Martens, E. (Ed.), & McFall-Ngai, M. J. (Ed.) (2017). Lactobacillus acidophilus Metabolizes Dietary Plant Glucosides and Externalizes Their Bioactive Phytochemicals. mBio (Online), 8(6), e01421-17. https://doi.org/10.1128/mBio.01421-17

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
**Lactobacillus acidophilus** Metabolizes Dietary Plant Glucosides and Externalizes Their Bioactive Phytochemicals

Mia C. Theilmann,a Yong Jun Goh,b Kristian Fog Nielsen,a Todd R. Klaenhammer,b Rodolphe Barrangou,b Maher Abou Hachem*a
Department of Biotechnology and Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmarka; Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, North Carolina, USAb

**ABSTRACT** Therapeutically active glycosylated phytochemicals are ubiquitous in the human diet. The human gut microbiota (HGM) modulates the bioactivities of these compounds, which consequently affect host physiology and microbiota composition. Despite a significant impact on human health, the key players and the underpinning mechanisms of this interplay remain uncharacterized. Here, we demonstrate the growth of *Lactobacillus acidophilus* on mono- and diglucosyl dietary plant glycosides (PGs) possessing small aromatic aglycones. Transcriptional analysis revealed the up-regulation of host interaction genes and identified two loci that encode phospho-transferase system (PTS) transporters and phospho-β-glucosidases, which mediate the uptake and deglucosylation of these compounds, respectively. Inactivating these transport and hydrolysis genes abolished or severely reduced growth on PG, establishing the specificity of the loci to distinct groups of PGs. Following intracellular deglucosylation, the aglycones of PGs are externalized, rendering them available for absorption by the host or for further modification by other microbiota taxa. The PG utilization loci are conserved in *L. acidophilus* and closely related lactobacilli, in correlation with versatile growth on these compounds. Growth on the tested PG appeared more common among human gut lactobacilli than among counterparts from other ecologic niches. The PGs that supported the growth of *L. acidophilus* were utilized poorly or not at all by other common HGM strains, underscoring the metabolic specialization of *L. acidophilus*. These findings highlight the role of human gut *L. acidophilus* and select lactobacilli in the bioconversion of glycoconjugated phytochemicals, which is likely to have an important impact on the HGM and human host.

**IMPORTANCE** Thousands of therapeutically active plant-derived compounds are widely present in berries, fruits, nuts, and beverages like tea and wine. The bioactivity and bioavailability of these compounds, which are typically glycosylated, are altered by microbial bioconversions in the human gut. Remarkably, little is known about the bioconversion of PGs by the gut microbial community, despite the significance of this metabolic facet to human health. Our work provides the first molecular insights into the metabolic routes of diet relevant and therapeutically active PGs by *Lactobacillus acidophilus* and related human gut lactobacilli. This taxonomic group is adept at metabolizing the glucoside moieties of select PG and externalizes their aglycones. The study highlights an important role of lactobacilli in the bioconversion of dietary PG and presents a framework from which to derive molecular insights into their metabolism by members of the human gut microbiota.

**KEYWORDS** *Lactobacillus*, beta-glucoside, bioavailability, gut microbiota, phytochemical, polydatin, polyphenols, resveratrol, xenobiotic metabolism
The human gut microbiota (HGM) exerts a profound impact on human health and developmental biology (1–3), in part through interplay with diet as well as metabolism of xenobiotics (4) and nondigestible carbohydrates (5). These impressive metabolic capabilities are encoded by a vast metagenome that outnumbers the genes of the human genome by more than 150-fold. Preferential carbohydrate metabolism is a key factor that shapes the HGM (6–8), whereby specific taxa adapt to different biogeographic and metabolic niches in the gut (9–11). The impact of the HGM composition on health has been well established through metagenomics and association studies (2, 12), but the functional understanding of the interplay between HGM and various dietary components remains limited.

A plethora of phytochemicals occur in fruits, berries, nuts, and vegetables and also in beverages, such as wine and tea (13). These compounds are frequently glycoconjugated in planta to enable storage and solubility or to modulate biological activity (14). Several phytochemicals, e.g., some phenolic and polyphenolic compounds, exhibit beneficial health effects via anti-inflammatory, antiestrogenic, cardioprotective, anticarcinogenic, chemopreventative, neuroprotective, antimicrobial, or antioxidant properties (15, 16). The biological activity varies depending on the glycoconjugation of the phytochemical (17). Stimulation or lack of inhibition of growth of lactobacilli on a few available glycosylated phytochemicals, here referred to as plant glycosides (PGs), has been reported (18, 19), but the role of lactobacilli in the bioconversion of PG has not been clear to date.

Lactobacillus acidophilus NCFM, a widely used probiotic, is a well-characterized model for human gut-adapted lactobacilli (20, 21), owing to its tolerance to bile (22), adhesion to epithelial cells and mucus (23, 24), and ability to colonize the host. Additionally, the abilities of this strain to take up and catabolize a variety of nondigestible complex carbohydrates have been documented and implicated in gut persistence (25–27). Lactobacilli rely on phosphotransferase systems (PTS) in the uptake of most carbohydrates (28). The genomes of human gut lactobacilli are expanded with PTS genes, compared to genomes of counterparts from more carbohydrate-poor ecologic niches (e.g., dairy or food), but functional assignment is lacking for most of these transporters. To a lesser extent, lactobacilli also possess ATP-binding cassette (ABC) importers for uptake of nutrients and ABC exporters, for which the specificities of most are unknown.

Here, we demonstrate the growth of L. acidophilus NCFM on chemically diverse and nutritionally relevant PG. We also elucidate a new metabolic strategy, involving the uptake of PG via two different PTS and intracellular hydrolysis by specialized phospho-β-glucosidases (P-Bgls), followed by the externalization of the aglycone moieties into culture supernatants. The PG utilization loci are conserved in the L. acidophilus species and closely related lactobacilli and correlate with versatile growth on these compounds. Growth on the tested PG appeared more common in human gut lactobacilli than for counterparts from other ecologic niches. The PG that supported the growth of L. acidophilus were utilized poorly or not at all by other common HGM strains, underscoring the metabolic specialization of L. acidophilus. These findings highlight the role of human gut L. acidophilus and select lactobacilli in modulating the availability and bioactivity of glycoconjugated phytochemicals, and these modulations are likely to have an important impact on the HGM and their host.

RESULTS

L. acidophilus NCFM grows on nutritionally relevant plant glycosides. The growth of L. acidophilus NCFM was evaluated on 11 chemically diverse, nutritionally relevant, and/or therapeutically active PG after 24 h of growth (Fig. 1; see Table S1 in the supplemental material). The cyanogenic diglucoside amygdalin, coumarin glucosides esculin and fraxin, alcoholic glucoside salicin, and aldehyde glucoside vanillin 4-O-β-glucoside all supported growth to a maximum optical density at 600 nm (OD600) of 0.3 to 1.3 in 200-μl cultures in 96-well plates. The poor solubility of the stilbenoid polydatin precluded use of the OD600 as a growth metric, but growth on this bioactive
A compound was verified by the production of lactate and metabolite analysis (described below). Additional Lactobacillus strains from different ecologic niches were tested for growth on the PGs amygdalin, arbutin, esculin, and salicin, as well as the control disaccharides, cellobiose, and glucose. L. acidophilus displayed versatile growth on PG, together with Lactobacillus plantarum subsp. plantarum and a Lactobacillus rhamnosus strain (Table S2). Generally, the ability to grow on PG was more common in strains isolated from the human gut niche than in counterparts from other ecological environments.

Growth on plant glucosides upregulates carbohydrate metabolism and host interaction genes in L. acidophilus NCFM. Global transcription was analyzed by transcriptome sequencing (RNA-Seq) in early- to mid-exponential-phase L. acidophilus NCFM cultures growing on lactose or glucose, as well as the growth-supporting PGs amygdalin, esculin, and salicin, which were selected based on their availability and chemical diversity.

The growth on lactose and the PGs differentially upregulated less than 10% of the 1,832 predicted protein-coding genes, compared to glucose (Table S3). Only 2% of the genes were highly upregulated on PG (Table 1). Of the upregulated genes, 55 were shared by two or more of the PG, whereas 58, 35, and 0 were uniquely induced by amygdalin, esculin, and salicin, respectively, indicating more extensive and unique cellular responses to amygdalin and to a lesser extent esculin than to salicin. Amygdalin, which supported the lowest level of growth, interestingly upregulated the highest number of genes (116 genes), followed by esculin (87 genes) and salicin (33 genes).

Carbohydrate metabolism and transport genes comprised about one-third of the differential transcriptome. Notably, three genes encoding α-glucan utilization enzymes were highly upregulated, including a GH31 putative α-glucosidase, a GH4 putative isomaltose-6′-phosphate α-glucosidase (LBA1689), which likely confers the breakdown of isomaltose (26), and a putative maltogenic α-amylase (LBA1871), which resides in the maltodextrin utilization cluster (29) (Table 1). The physiological significance of such upregulation is unclear, but α-glucans from starch breakdown by humans and bacteria are common metabolic resources in the small intestine, which is inhabited by lactobacilli (30), and this may explain the observed response. The transcriptional response also revealed the upregulation of genes encoding proteins predicted to be associated with mucus, fibrinogen, and epithelial cell adhesion, e.g., LBA0649, LBA1392, LBA1633, and LBA1709 (Table 1; Table S3) (24, 31, 32). Interestingly, genes encoding cellular defense
redox enzymes, e.g., a peroxidase (LBA1401) and an oxidoreductase (LBA1025), were also upregulated, indicating a possible xenobiotic stress response (Table 1; Table S3). Multidrug efflux ABC export systems were also upregulated, e.g., LBA0574 and LBA0575, together with 41 hypothetical proteins (Table S3). Growth on PG appeared to promote increased host interaction and adhesion, which was also observed for *L. rhamnosus* after pretreatment with the PG rutin and phloridzin (33).

Specific phosphotransferase uptake systems and specialized phospho-β-glucosidases are essential for growth on plant β-glucosides. Growth on PGs highly upregulated two gene loci compared to growth on glucose (Table 1; Table S3), and these findings were also corroborated by quantitative reverse transcriptase PCR (qRT-PCR) analysis (data not shown). The first locus encompassed four genes which were highly upregulated (log2 ratios of 4.1 to 8.9, corresponding to 17- to 478-fold upregulation) for all 3 PG. The genes encode a LicT transcriptional antiterminator (LBA0724), an EIIABC component of a phosphotransferase system (PTS; LBA0725), a phospho-β-glucosidase (P-Bgl; LBA0726) of glycoside hydrolase family 1 (GH1) according to the CAZy database (34), and a hypothetical protein (LBA0728) (Fig. 2A). These genes, except for the less frequently transcribed LBA0728, which belongs to the *Lactobacillus* core genome (35), are among the top 10% most upregulated genes in the PG transcriptomes (Table S3). The second locus, which was only transcriptionally responsive to amygdalin, encodes another P-Bgl of GH1 (LBA0225), a divergently transcribed PTS enzyme II component (EIC; LBA0227), and a transcriptional regulator (LBA0228) (Fig. 2B). Both

### Table 1: Highly upregulated genes in the transcriptome of *L. acidophilus* NCFM grown on amygdalin, esculin, or salicin

| Locus tag | Annotation | COG | Log2 ratio | Amy/Glc | Esc/Glc | Sal/Glc |
|-----------|------------|-----|------------|---------|---------|---------|
| LBA0227  | PTS EIIIC  | G   | 9.9        | 0.8     | 0.9     |
| LBA0725  | PTS EIIABC | G   | 9.7        | 9.8     | 8.9     |
| LBA0726  | Phospho-β-glucosidase (GH1) | G   | 7.2        | 6.9     | 6.2     |
| LBA1436  | Glycerol uptake facilitator protein | G   | 7.2        | 4.9     | 3.8     |
| LBA0631  | Hypothetical protein | G   | 7.2        | 2.9     | 2.9     |
| LBA1435  | Hypothetical protein | S   | 7.1        | 5.0     | 3.6     |
| LBA1434  | Dihydroxyacetone kinase | G   | 6.7        | 4.5     | 3.3     |
| LBA1869  | β-Phosphoglucomutase | R   | 6.7        | 4.2     | 2.4     |
| LBA1684  | PTS EIIA   | G   | 6.6        | 2.9     | 2.6     |
| LBA0225  | Phospho-β-glucosidase (GH1) | G   | 6.5        | -0.2    | -0.1    |
| LBA0724  | Transcriptional regulator (antiterminator) | K   | 6.4        | 5.5     | 5.3     |
| LBA0228  | Transcriptional regulator | G   | 6.3        | 0.9     | 0.1     |
| LBA1433  | Dihydroxyacetone kinase | G   | 6.0        | 3.7     | 2.7     |
| LBA0728  | Hypothetical protein | R   | 6.0        | 4.8     | 4.1     |
| LBA0555  | Myosine-cross-reactive antigen/fatty acidhydratase | S   | 6.0        | 2.0     | 1.4     |
| LBA1974  | Pyruvate oxidase | E   | 5.5        | 3.6     | 1.8     |
| LBA1689  | Isomaltose-6'-phosphate glucosidase (GH4) | G   | 5.3        | 1.8     | 3.7     |
| LBA1812  | α-Glucosidase II (GH31) | G   | 5.3        | 2.8     | 2.2     |
| LBA1701  | Melibiose operon regulatory protein | K   | 5.3        | 4.9     | 1.0     |
| LBA0466  | Phosphoenolpyruvate carboxykinase (ATP) | C   | 5.2        | 2.0     | 1.3     |
| LBA0492  | Hypothetical protein | G   | 5.1        | 3.7     | 2.2     |
| LBA0606  | PTS EIIIC | G   | 4.9        | 2.8     | 2.5     |
| LBA0491  | PTS EIIA | G   | 4.7        | 3.4     | 1.5     |
| LBA1797  | Hypothetical protein | G   | 4.7        | 2.6     | 1.3     |
| LBA0877  | PTS EIIA | G   | 4.6        | 3.0     | 1.3     |
| LBA1873  | Acetate kinase | C   | 4.6        | 0.8     | 1.2     |
| LBA1709  | Mucus binding protein precursor | G   | 4.5        | 3.6     | 0.5     |
| LBA1632  | NAD-dependent aldehyde dehydrogenase | C   | 4.4        | 3.3     | 2.0     |
| LBA1401  | Peroxidase (Npx) | R   | 4.4        | 3.1     | 2.7     |
| LBA0876  | PTS EIIA | G   | 4.4        | 2.9     | 2.4     |
| LBA1871  | Maltogenic α-amylase (GH13) | G   | 4.3        | 2.1     | 0.9     |
| LBA1411  | Fumarate reductase flavoprotein subunit | C   | 4.0        | 1.7     | 1.4     |

*a* Annotations are based on homology or functional characterization when possible.

*b* COG, cluster of orthologous group classification; C, energy production and conversion; E, amino acid metabolism and transport; G, carbohydrate metabolism and transport; K, transcription; R, general functional prediction only; S, function unknown.

*c* Differential transcription log2 ratio of normalized transcripts per million relative to glucose. Amy, amygdalin; Esc, esculin; Sal, salicin; Glc, glucose. The included genes displayed log2 differential expression ratios (of the normalized transcripts per million) of $\geq 4$ for the plant glycosides.
these gene loci are strictly conserved in the *L. acidophilus* species and to some extent in related lactobacilli from the *L. delbrueckii* group (Fig. 2; Table S4).

To establish the functional significance of these two loci, constructs with single deletions of each PTS EII and P-Bgl gene or a double deletion of both P-Bgl genes were created by using the *upp*-based counterselectable gene replacement system (36) (Table S5), and the growth phenotypes of the mutant strains were analyzed (Fig. 3). This analysis is very powerful, particularly as the physiological 6'-phosphorylated substrates...
Theilmann et al.

FIG 3 Phenotypic growth analyses of deletion mutants of EII PTS transporters (left) and phospho-β-glucosidases (right) on the β-glucosides esculin, salicin, and amygdalin, and the disaccharides gentiobiose and cellobiose. The background Δupp strain is shown in gray, and the growth of the mutant strains is shown for PTS EIIC (LBA0227; pink triangle), the phospho-β-glucosidase (LBA0225; light blue triangles), the PTS EIIABC (LBA0725; yellow squares), the second phospho-β-glucosidase (LBA0726; lilac squares), and the double phospho-β-glucosidase mutant (LBA0225/LBA0726; black stars). The color scheme is consistent with that used for the gene loci in Fig. 2. The growth experiments were performed in biological triplicates, and the average errors were <6%.

of the GH1 enzymes are not available to perform enzymatic analyses in vitro. The growth of the ΔLBA0725 mutant (with an inactive PTS EIIABC) was abolished on esculin or salicin, severely reduced on amygdalin, and moderately reduced on cellobiose or gentiobiose. The abolished growth on esculin and salicin identified this EIIABC as the
sole transporter for these PG, but the reduced growth on the other compounds suggested additional roles for this transport system. The growth profile of the ΔLBA0726 mutant, which lacks a functional P-Bgl, was similar on PGs, but growth on either cellobiose or gentiobiose was unaffected. This phenotype also supports the specificity of P-Bgl (LBA0726) toward the PGs esculin and salicin (Fig. 3). Accordingly, we can assign the specificity of this locus to the uptake and hydrolysis of PGs, with a preference for distinct monoglucosylated small aromatic aglycones.

The growth of the ΔLBA0227 mutant (inactive ElIC) in the second locus, which was exclusively upregulated by amygdalin, was abolished on both amygdalin and gentiobiose (Fig. 3E and G), both of which share a β-(1,6)-diglucoside moiety (Fig. 1). The phenotypes for salicin and esculin were invariant compared to the wild-type strain (Fig. 3A and C). These data provided compelling evidence for the specificity of this PTS ElIC transporter for amygdalin and gentiobiose, consistent with previously reported upregulation in response to gentiobiose (26). This specificity is also supported by the phenotype of the P-Bgl mutant ΔLBA0225. The severe reduction in growth for the ΔLBA0225 mutant lacking the P-Bgl from the first locus on amygdalin (Fig. 3F), but not on gentiobiose (Fig. 3H), suggests a role for this enzyme in the catabolism of amygdalin. Indeed, growth on amygdalin was only abolished with the double P-Bgl mutant (Fig. 3F). The identification of low levels of prunasin, the singly deglucosylated form of amygdalin (Table S6), suggests that the deglycosylation of amygdalin occurs in two steps, with sequential cleavage of the nonreducing β-(1,6)-linked glucosyl by the P-Bgl that recognizes the β-(1,6)-gentiobiose moiety (LBA0225) and by a second P-Bgl that cleaves monoglucosylated compounds (LBA0726) to release the aglycone moiety. Based on these data, we can assign the specificity of the locus encoding the PTS ElIC transporter (LBA0227) and the phospho-β-glucosidase (LBA0225) to compounds with a β-(1,6)-diglucoside motif, like gentiobiose and amygdalin. The full deglycosylation of PGs possessing a gentiobiose moiety like amygdalin, however, required the additional activity of the second P-Bgl (LBA0726).

*L. acidophilus* cells externalize the bioactive aglycones of PGs and preferentially utilize glucosides that support the highest growth levels. We monitored the growth of *L. acidophilus* NCFM and analyzed the metabolites in the culture supernatants at 0 and 24 h. The PG were identified in the preculture medium (Table S6). Depletion of the PGs that supported growth (Fig. 1) was proportional to growth (the final OD600), and the respective aglycones lacking the glucosyl moiety (loss of 162 Da) (Table S6) were identified in the culture supernatants. The growth on polydatin was verified from the extent of depletion (Fig. 1), the identification of the aglycone resveratrol (Table S6), and the production of lactate. The only deviation from this trend was the absence of the aglycone of amygdalin (mandelonitrile). Instead, the main metabolite of amygdalin utilization was benzaldehyde, which was only detectable by UV, due to its volatility. The PGs that did not support growth persisted, and no metabolites of these PGs were detected at 24 h.

We also monitored the temporal changes in concentrations of the three most available PGs, salicin, esculin, and amygdalin, and of their metabolites in culture supernatants. The concentration of salicin decreased throughout the growth period (Fig. 4A; Fig. S1), while an inverse trend was observed for the aglycone salicyl alcohol during exponential-phase growth. Notably, the aglycone moiety of salicin *per se* was unable to support growth of *L. acidophilus* (data not shown). The same pattern was observed for esculin, which was depleted concomitantly with the increase in the concentration of the aglycone metabolite esculetin during the first 12 h of growth (Fig. S1).

The concentration of amygdalin in the culture supernatant also decreased steadily, concomitant with an increase in benzaldehyde (Fig. S1). In contrast to the other 2 PGs, however, only about one-third of the initial amygdalin was utilized during 24 h of growth, and the summed concentration of amygdalin and benzaldehyde was invariant over time. Low levels of the monodeglucosylated metabolite of amygdalin, prunasin (37), were identified (Table S6). Although the corresponding aglycone, mandelonitrile,
FIG 4 Time-resolved metabolite analysis of *L. acidophilus* NCFM grown on plant glucosides. (A) Time course depletion of salicin and appearance of its aglycone salicyl alcohol in the culture supernatants, visualized as the area under the $A_{270}$ peaks in the UHPLC–qTOF-MS chromatograms. (B) Preference of *L. acidophilus* NCFM for plant glycosides during growth on an equimolar mixture of salicin, esculin, and amygdalin. Salicin was preferred, followed by esculin, while amygdalin was hardly consumed after 24 h. The aglycones of the plant glucosides and the concentration of lactate increased concomitantly with growth.
was identified in the first 6 h ([M + CH₃COO]⁻ adduct; m/z 192.0664), the main amygdaлин metabolite was benzaldehyde, which is produced via a hydrogen cyanide elimination reaction of mandelonitrile. This reaction is catalyzed by nitrile lyase but has also been reported to occur spontaneously (38). This is the likely scenario for our experiment, as no nitrile lyase is encoded by *L. acidophilus*. Detection of traces of scopoletin, the methylated form of the esculin aglycone (Table S6), was the only evidence for enzymatic modification of the aglycones of PG, but the paucity of this species casts doubt on the specificity of this modification. Taken together, our metabolite analyses are supportive of *L. acidophilus* largely exporting noncarbohydrate moieties without enzymatic modification. The mechanism of externalization is not clear, but the export systems, e.g., an ATP-binding cassette exporter in the case of esculin (LBA0573 to LBA0575), are upregulated in the transcriptome (Table S3).

To evaluate whether amygdaлин, esculin, and salicin are taken up randomly or according to a certain preference, we analyzed the supernatants of *L. acidophilus* NCFM grown on equimolar concentrations of these PG. Strikingly, salicin was the first compound to be fully depleted, followed by esculin, whereas significant amounts of amygdaлин persisted after 24 h of growth (Fig. 4B), thus establishing the clear preference of *L. acidophilus* in the utilization of PG that support its best growth.

**DISCUSSION**

A considerable proportion of the thousands of diet-derived known phytochemicals mediates positive health effects in humans (39). The daily intake of phytochemicals is relatively high due to the enrichment of common nutritional sources, such as fruits, berries, nuts, vegetables, herbs, and beverages such as wine and tea (13). Frequently, phytochemicals occur as glycoconjugates that exhibit lower bioactivity and bioavailability than their aglycone derivatives, which are smaller in size and typically less polar (40, 41). Therefore, deglycosylation of PGs is likely an important factor in modulating their biological activity (42). The health impact of HGM-mediated biotransformation of drug xenobiotics and diet-derived phytochemicals has gained considerable interest (4, 43). Our insight into this latter metabolic aspect of the HGM is conspicuously limited. The small intestine is the primary site for absorption of nutrients and xenobiotics, which lends extra gravity to the metabolic activities of HGM prevalent in this part of the gastrointestinal tract, where lactobacilli constitute an important part of the microbial population (11). Based on our findings, we report here the versatility of the probiotic bacterium *L. acidophilus* NCFM in utilization of dietary therapeutically active PG, revealing that only the carbohydrate moieties are catabolized while the aglycones are externalized, making them bio-accessible to absorption by the host or available for further interactions with other organisms of the HGM.

Carbohydrates are mainly taken up by PTS transporters in lactobacilli (28, 44). Translocation is coupled to phosphorylation of the glycoside mostly at the 6'-position via an enzymatic cascade that relays the phosphoryl group to a substrate-specific EIIC complex (45). The EIIC forms the translocation channel that defines the specificity of the EII complex. Phosphorylation is relayed via EIIC and EIIB enzymes, of which the latter is known to interact specifically with EIIC. The EII modules are either encoded by a single gene, e.g., the gene for the EIIABC salicin and esculin uptake system (LBA0725), or by 2 to 3 separate genes, to assemble the phosphorylation cascade. The amygdaлин EIIC component (LBA0227) requires coupling from EIIC and EIIB modules that are not encoded by the same locus. This EIIC is only upregulated upon growth on its substrate, amygdaлин, whereas the LBA0725 EIIABC is highly upregulated during growth on the substrates salicin and esculin, as well as on amygdaлин (Table 1; Fig. 3 and 5). Accordingly, inactivation of the EIIC elicits an impaired growth phenotype only on the substrate amygdaлин, whereas the inactivation of the EIIABC causes an approximate 50% reduction of growth on amygdaлин, as well as on the two disaccharides cellobiose and gentiobiose, both of which are not hydrolyzed by the P-Bgl encoded by this locus (Fig. 3). The lack of growth on amygdaлин or gentiobiose, when the EIIC system is inactivated, precludes uptake of these compounds solely via the EIIABC system. A
possible rationale for the coregulation of the two transporters and the phenotypic impact of the EIIABC on nonsubstrates is that the EIIA and/or EIIB components of LBA0725 contribute in coupling phosphorylation to the amygdalin EIIC system and possibly to other EIIC modules. The less drastic phenotype of EIIABC on nonsubstrates, however, suggests that the contribution of this transporter can be complemented by other PTS systems. To our knowledge, this functional overlap between PTS systems that are assigned to different families (46) has not been reported before and merits further investigation. Such an overlap may orchestrate interplay between different transporters to confer the uptake of diverse sugars by bacteria.

There is a large and growing body of evidence on functionalities of phytochemicals and their beneficial health effects (i.e., nutraceuticals) (39, 47, 48). Several intervention studies have shown changes in HGM composition, especially an increase in lactobacilli and bifidobacteria, due to phytochemicals, which are also suggested to have antimicrobial effects (7, 49, 50). The routes of conversion of these compounds, however, have not been addressed at the molecular level. Our data suggest an important role of human gut L. acidophilus in the activation of dietary-relevant PG (Fig. 5). For example, salicin, the best growth substrate for L. acidophilus NCFM in this study, is a pharmacologically inactive precursor of the analgesic and antirheumatic drug salicylic acid. Indeed, salicylic acid has been reported to be the main metabolite (86%) in serum after oral administration of salicin-rich willow bark extract in humans (51). Our study revealed that L. acidophilus performs a step in this bioactivation, via deglycosylation and...
externalization of salicyl alcohol, which becomes accessible for oxidation to salicylic acid performed by other microbiota. Fraxin, which also sustains the growth of *L. acidophilus*, is one of the active ingredients in some Chinese and Japanese herbal medicines and has several potential positive health effects, including protection against oxidative stress (52). *L. acidophilus* also converts polydatin, which is enriched in wines and tea, to resveratrol, which is one of the most-studied therapeutic phytochemicals due to its implication in protection against, e.g., inflammation, cancer, and obesity (53–55). Other lactobacilli have also been implicated in the metabolism of other PGs, e.g., the *in vitro* conversion of the isoflavonic daidzin, present in soy products, by the pig intestinal commensal *Lactobacillus mucosae* EPI2, to the estrogen-mimicking aglycone equol, which has been proposed to be protective against breast cancer (56, 57).

*In silico* analysis of genomic sequences of *L. acidophilus* strains revealed the conservation of the PG utilization loci identified in the present study, indicating the potential ability of this species to metabolize PGs (Table S4). Our growth survey using four different PG revealed large species variations in growth (Table S2). Generally, *L. acidophilus* strains were among the top strains in terms of growth on PG, and lactobacilli strains from the gut appeared to better at PG utilization than counterparts from other ecological niches, suggesting a competitive advantage in the adaptation to the human gut environment. Gene landscape analyses showed a correlation between growth on salicin or esculin and the presence of the intact LBA0724-LBA0726 locus in the tested strains that belong to the taxonomically closely related *L. delbrueckii* clade, i.e., *L. acidophilus*, *Lactobacillus crispatus*, *Lactobacillus jensenii*, and *Lactobacillus gasseri* (58) (Fig. 2A). Strains missing one or more genes within this cluster or which have a fragmented version of the LBA0725 transporter gene were conversely unable to grow on esculin or salicin (Table S2). Growth on amygdalin is less common within the *L. delbrueckii* group, in line with the limited occurrence of the amygdalin gene cluster (LBA0225 to LBA0228). The *L. amylovorus* strain has a fragmented and likely dysfunctional version of EIIABC LBA0725 (Fig. 2A, total sequence coverage of 72%). This strain is unable to grow on amygdalin, consistent with the involvement of modules from this PTS in the uptake of β-(1,6)-glucosides, as discussed above. The good growth of more distant species, e.g., *Lactobacillus plantarum* subsp. *plantarum* and *Lactobacillus rhamnosus* GG, which lack the gene locus, discloses the presence of alternative routes for the utilization of amygdalin in other *Lactobacillus* clades. The functional data in the present study, combined with the genetic analysis, provide an extended predictive power for PG utilization within closely related lactobacilli, although the metabolic pathways and transporters are likely to be diverse across a larger taxonomic group. Although our limited screening was not sufficient to establish PG utilization in other microbiota taxa, our results do hint at the specialization of *L. acidophilus* growth on PGs that are not utilized by other common taxa (Fig. S2).

Taken together, this study enabled the elucidation of a novel pathway for the bioconversion of PGs and the externalization of their bioactive aglycones by the human gut-adapted *L. acidophilus* and closely related taxa. The bioconversion of PG is accompanied by a modulation of the activities of the phytochemicals in the small intestine, which renders these compounds bioavailable for further functional interplay with the host and other HGM taxa (Fig. 5). In conclusion, this study casts light on underexplored facets of the metabolism of plant-derived glycosides and their bioconversion by the microbiota that exert a significant impact on human health. Further work is required to bring insight on the fate of PG in the human gut ecological niche and to evaluate the clinical and possible therapeutic implications of PG bioconversion by the HGM.

**MATERIALS AND METHODS**

**Chemicals and carbohydrates.** The plant glycosides utilized in this work are described in Table S1. All other chemicals used were of high purity.

**Bacterial strains and growth.** Bacterial strains and plasmids used in this study are presented in Table S5. *Lactobacillus* strains were propagated statically in de man-Rogosa-Sharp (MRS) broth (Difco Laboratories, Detroit, MI) under aerobic conditions or on MRS agar plates (1.5% [wt/vol]; Difco) under anaerobic conditions at 37°C, or at 42°C for pTRK669 elimination (59). Recombinant *L. acidophilus* strains
were selected in the presence of 2 μg ml⁻¹ erythromycin (Sigma-Aldrich, St. Louis, MO, USA) and/or 2 to 5 μg ml⁻¹ chloramphenicol (Sigma). Selection of plasmid-free double recombinants was done on a semidefined agar medium containing 2% (wt/vol) glucose (SDM) with 100 μg ml⁻¹ 5-fluorouracil (5-FU; Sigma), as described by Goh et al. (36).

For initial growth and gene expression studies, L. acidophilus NCFM was propagated three times in a semidefined medium supplemented with either 1% or 0.5% (wt/vol) of the plant glycoside or carbohydrate (Table S1). The plant glycoside screening was carried out in at least biological triplicates. For the RNA-Seq analysis, cells were harvested by centrifugation (3,220 × g, 10 min, 25°C) in the mid-exponential phase (OD600, 0.6 to 0.8) and stored at −80°C for subsequent RNA isolation. For the mass spectrometry metabolite analyses, 200-μl samples were taken at 0, 3, 6, 9, 12, and 24 h of growth, cells were removed by centrifugation, and supernatants were stored at −80°C for further analysis.

Phenotypic growth assays were performed using 1% (vol/vol) overnight cultures of L. acidophilus strains (Table S5) and other Lactobacillus species (Table S2) grown on SDM supplemented with 1% (wt/vol) glucose to inoculate 200 μl of SDM supplemented with 1% (wt/vol) of the examined carbohydrate (0.5% in the case of esculin) in 96-well microplate wells (Corning Costar, Corning, NY). Phenotypic growth assays of L. acidophilus NCFM and its knockout variants were performed in biological triplicates, whereas the growth screening of other L. acidophilus strains or other Lactobacillus species was performed in biological duplicates. The microplates were sealed with clear adhesive film and incubated at 37°C in a Fluostar Optima microplate reader (BMG Labtech, Cary, NC), and the culture OD600 was monitored for 30 h.

Escherichia coli EC101, used for generating the L. acidophilus gene knockouts, was grown in brain heart infusion (BHI) broth (Difco) at 37°C with aeration in the presence of kanamycin (40 μg ml⁻¹). Recombinant E. coli EC101 cells containing pTR935-based plasmids were selected with erythromycin (150 μg ml⁻¹). Growth of the extracted RNA, and further purification was carried out using the RNA Clean and Concentrator 5 kit (Zymo Research). The quality of RNA was analyzed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and the absence of genomic DNA was confirmed by PCR using L. acidophilus NCFM gene-specific primers. Library preparation and RNA sequencing were performed by the High-Throughput Sequencing and Genotyping Unit of the Roy J. Carver Biotechnology Centre, University of Illinois (Urbana-Champaign, IL). After rRNA removal (using a Ribob-Zero rRNA removal kit for bacteria; Illumina, San Diego, CA), library preparation was carried out using the TruSeq stranded total RNA library prep kit (Illumina). Single-read RNA sequencing was performed using a HiSeq 2500 ultrahigh-throughput sequencing system (Illumina) and the Illumina HiSeq SBS v4 kit (Illumina) with a read length of 160 nucleotides (nt). The raw reads were demultiplexed with the bcl2fastq conversion software (v 2.17.1.14; Illumina), trimmed for the adapter sequences, quality trimmed to remove sequence reads with an error probability threshold of 0.001 (Phred score, 30), and filtered to remove reads of <20 nt by using Geneious version 9.0.4 (62). The quality of the reads was assessed by using FastQC v0.11.5 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). The resulting reads were then mapped to the L. acidophilus NCFM reference genome by using the Geneious Mapper with default settings (62). The sequencing coverage depths were calculated to be 610× to 692×, and transcriptional analyses were based on the number of normalized transcripts per million (nTPM), calculated within Geneious. Differentially expressed genes were defined as having a log2 ratio of ≥2 unless otherwise stated.

RT-qPCR assay. To confirm the results of the RNA-Seq transcriptional study, RT-qPCR analysis of selected genes was performed (63). Briefly, the iTaq universal SYBR green one-step kit (Bio-Rad Laboratories, Hercules, CA) was used according to the manufacturer’s instructions, except for scaling down to 25-μl reaction mixtures with 50 ng of RNA template and 300 nM of each primer (Table S7). An iCycler MyIQ single-color detection system (Bio-Rad) was used, and the data were analyzed using iCycler MyIQ software v1.0 (Bio-Rad). The correlation coefficients for the standard curves and PCR efficiencies were between 0.930 and 0.999 and 88.7% to 102.5%, respectively.

DNA manipulation and transformation. Genomic DNA from L. acidophilus NCFM and mutants thereof was isolated using the ZR fungal/bacterial DNA MiniPrep kit (Zymo Research). Plasmid DNA was isolated using the QIAprep Spin MiniPrep kit (Qiagen, Hilden, Germany). Restriction enzymes were from Roche (Basel, Switzerland), and T4 DNA ligase was from NEB (New England Biolabs, Ipswich, MA). Phusion HI fusion HS DNA polymerase (Agilent Technologies, Santa Clara, CA) was used for cloning, and Choice-Taq Blue DNA polymerase (Denville Scientific, South Plainfield, NJ) was used for PCR screening of recombinants. PCR amplicons were analyzed on 0.8% (wt/vol) agarose gels and extracted using the QIAquick gel extraction kit (Qiagen). DNA sequencing was performed by Eton Biosciences (Durham, NC).

Construction of gene deletion mutants. The L. acidophilus NCFM genes LBA0225 and LBA0726, both of which encode P-Bgl of glycoside hydrolase family 1 (GH1) enzymes (34), in addition to the LBA0227 and LBA0725 genes which encode EIIc and EIaABC components of two PTS, respectively (64),
were deleted using the upp-based counterselectable gene replacement system (36). Briefly, in-frame deletions were constructed by amplifying 650 to 750 bp of the up- and downstream flanking regions of the deletion targets with two primer pairs, e.g., LBA0225A/LBA0225B and LBA0225C/LBA0225D (Table S7). The resulting purified products were joined by splicing using overlap extension PCR (SOE-PCR) and amplified to establish the deletion alleles. The SOE-PCR products, which included flanking restriction enzyme sites, were cloned within the BamHI and SacI/EcoRI sites of the pTRK935 integration vector and transformed into E. coli EC101. The resulting recombinant plasmids (pTRK1113 to -6) were confirmed by DNA sequencing and electroporated into L. acidophilus NCK1910 (Table SS), which contains the pTRK669 helper plasmid, and recovery of single- and double-crossover recombinants was performed as previously described (63). Recombinants carrying the new gene deletion alleles were isolated by colony PCR using primer pairs denoted up-down (e.g., LBA0225up/LBA0225down), which anneal to the flanking regions of the amplicons. Sequence integrity and in-frame deletions were verified by DNA sequencing employing the aforementioned primer pairs and a primer denoted mid (e.g., LBA0225mid). The mutations were in-frame deletions of 90 to 96% of the coding regions.

Analysis of plant glycoside uptake from L. acidophilus NCFM culture supernatants using mass spectrometry. The supernatants of L. acidophilus NCFM cultures grown on amygdalin, arbutin, esculin, or salicin as carbon sources were analyzed during 24 h by using ultrahigh-performance liquid chromatography–diode array detection–quadruple time of flight mass spectrometry (UHPLC–DAD–Q-TOF-MS). Samples were diluted 1:20 (vol/vol) with methanol, and an injection volume of 1.5 µl was used. Separation was carried out on an Agilent Poroshell 120 phenyl-hexyl column (2.1 by 150 mm, 2.7 µm) using the Infinity 1290 UHPLC system (Agilent Technologies, Santa Clara, CA) equipped with a UV-visible spectrometry–diode array detection–quadruple time of flight mass spectrometry (UHPLC–DAD–Q-TOF-MS). Samples were diluted 1:20 (vol/vol) with methanol, and an injection volume of 1.5 µl was used. Separation was carried out on an Agilent Poroshell 120 phenyl-hexyl column (2.1 by 150 mm, 2.7 µm) using the Infinity 1290 UHPLC system (Agilent Technologies, Santa Clara, CA) equipped with a UV-visible spectrometry–diode array detection–quadruple time of flight mass spectrometry (UHPLC–DAD–Q-TOF-MS).

SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio.01421-17.

FIG S1, PDF file, 0.3 MB.
FIG S2, PDF file, 0.1 MB.
TABLE S1, DOCX file, 0.03 MB.
TABLE S2, DOCX file, 0.02 MB.
TABLE S3, XLSX file, 0.1 MB.
TABLE S4, DOCX file, 0.02 MB.
TABLE S5, DOCX file, 0.02 MB.
TABLE S6, DOCX file, 0.02 MB.
TABLE S7, DOCX file, 0.02 MB.

ACKNOWLEDGMENTS
A provisional patent has been filed based on the data from this study. This research was funded by the Danish Research Council for Independent Research, Natural Sciences (grant 4002-00297 to M.A.H.).

REFERENCES
1. Charbonneau MR, Blanton LV, DiGiulio DB, Relman DA, Lebrilla CB, Mills DA, Gordon JL. 2016. A microbial perspective of human developmental biology. Nature 535:48–55. https://doi.org/10.1038/nature18845.
2. Sonnenburg JL, Bäckhed F. 2016. Diet-microbiota interactions as modulators of human metabolism. Nature 535:66–64. https://doi.org/10.1038/nature18846.
3. Zitoogel L, Ayyoub M, Routy B, Kroemer G. 2016. Microbiome and anticancer immunosurveillance. Cell 165:276–287. https://doi.org/10.1016/j.cell.2016.03.001.
4. Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. 2016. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol 14:273–287. https://doi.org/10.1038/nrmicro.2016.17.
5. Martens EC, Kelly AG, Tauzin AS, Brumer H. 2014. The devil lies in the details: how variations in polysaccharide fine-structure impact the physiology and evolution of gut microbes. J Mol Biol 426:3851–3865. https://doi.org/10.1016/j.jmb.2014.06.022.
6. Scott KP, Gratz SW, Sheridan PO, Flint HJ, Duncan SH. 2013. The influ-
ence of diet on the gut microbiota. Pharmacol Res 69:52–60. https://doi.org/10.1016/j.phrs.2012.02.010.

7. David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Wong AC, Ding H, McVey N, Termine JD, et al. 2014. Diet rapidly and reproducibly alters the gut microbiome. Nature 504:559–563. https://doi.org/10.1038/nature12820.

8. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A, Young VB, Henriissit B, Wilmes P, Stappenbeck TS, Núñez G, Martens EC. 2016. A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167:1339–1353.e21. https://doi.org/10.1016/j.cell.2016.10.043.

9. Rogowski A, Briggs JA, Mortimer JC, Tryfona T, Terrapon N, Lowe EC, Basile A, Morland C, Day AM, Zheng H, Rogers TE, Thompson P, Hawker M, Yadav MP, Henriissit B, Martens EC, Dupree P, Gilbert HJ, Bolam DN. 2015. Glicy complexity dictates microbial resource allocation in the large intestine. Nat Commun 6:7481. https://doi.org/10.1038/ncomms8481.

10. Cockburn DW, Koropatkin NM. 2016. Polysaccharide degradation by the intestinal microbiota and its influence on human health and disease. J Mol Biol 428:3320–3322. https://doi.org/10.1016/j.jmb.2016.06.021.

11. Donaldson GP, Lee SM, Mazmanian SK. 2016. Gut microbiota: a key player in the gut and its cross-talk with the host. Nat Rev Microbiol 14:24–30. https://doi.org/10.1038/nrmicro3552.

12. Wang J, Jia HJ. 2016. Metagenome-wide association studies: fine-mining the microbiome. Nat Rev Microbiol 14:508–522. https://doi.org/10.1038/nrmicro.2016.83.

13. Manach C, Scalbert A, Morand C, Rémyes C, Jiménez L. 2004. Polyphenols: food sources and bioavailability. Am J Clin Nutr 79:727–747.

14. Duda-Chodak A. 2012. The inhibitory effect of polyphenols on human gut microbiota. J Physiol Pharmac 63:497–503.

15. Scalbert A, Manach C, Morand C, Rémyes C, Jiménez L. 2005. Dietary polyphenols and the prevention of diseases. Crit Rev Food Sci Nutr 45:287–306. https://doi.org/10.1080/1040869059096958.

16. Vauzour D, Rodríguez-Mateos A, Corona G, Oruño-Concha MJ, Spencer JPE. 2010. Polyphenols and human health: prevention of disease and mechanisms of action. Nutrients 2:1106–1131. https://doi.org/10.3390/nu2111106.

17. Manach C, Williamson G, Morand C, Scalbert A, Rémyes C. 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81(1 Suppl):230–242.

18. Sanders ME, Klaenhammer TR. 2001. Invited review: the scientific basis of NCFM functionality as a probiotic. J Dairy Sci 84:319–331. https://doi.org/10.3168/jds.S0022-0302(01)74481-5.

19. O’Flaherty SJ, Klaenhammer TR. 2010. Functional and phenotypic characterization of a protein from Lactobacillus acidophilus involved in cell morphology, stress tolerance and adherence to intestinal cells. Microbiology 156:3360–3367. https://doi.org/10.1099/micro.0.043158-0.

20. Andersen JM, Barrangou R, Abou Hachem M, Lahtinen SJ, Ceoloni S, Mørk MS, Goh YJ, Rasmussen KB, Cypryk W, Klaenhammer TR. 2017. An extracellular cell-attached pullulanase concedes anchoring α-glucan utilization in human gut Lactobacillus acidophilus. Appl Environ Microbiol 83. https://doi.org/10.1128/AEM.00402-17.

21. Yang B, Chen HQ, Song YD, Chen YQ, Zhang H, Chen W. 2013. Myosine-cross-reactive antigens from four different lactic acid bacteria are fatty acid hydrolases. Biotechnol Lett 35:75–81. https://doi.org/10.1007/s10529-012-1044-y.

22. Buck BL, Alterman E, Svingerud T, Klaenhammer TR. 2005. Functional analysis of putative adhesion factors in Lactobacillus acidophilus NCFM. Appl Environ Microbiol 71:8344–8351. https://doi.org/10.1128/AEM.71.12.8344-8351.2005.

23. Parkar SG, Stevenson DE, Skinner MA. 2008. The potential influence of fruit polyphenols on colonic microflora and human gut health. Int J Food Microbiol 124:295–298. https://doi.org/10.1016/j.iflomicro.2008.03.017.

24. Lombard V, Ramulu HG, Drula E, Coutinho PM, Henriissit B. 2014. The carbohydrate-active enzymes database (CAzY) in 2013. Nucleic Acids Res 42:D490–DD495. https://doi.org/10.1093/nar/gkt1178.

25. Kant R, Blom J, Palva A, Siezen RJ, de Vos WM. 2011. Comparative genomics of Lactobacillus. Microbiot Biotechnol 4:323–332. https://doi.org/10.1111/j.1751-7915.2010.00215.x.

26. Goh YJ, Azcarate-Peril MA, O’Flaherty SJ, Durmaz E, Valence F, Jardin J, Lortal S, Klaenhammer TR. 2009. Development and application of a supplemented counterselective gene replacement system for the study of the s-layer protein slpX of Lactobacillus acidophilus NCFM. Appl Environ Microbiol 75:3093–3105. https://doi.org/10.1128/AEM.02502-08.

27. Ge BY, Chen HX, Han FM, Chen Y. 2007. Identification of amygdalin and its major metabolites in rat urine by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 857:281–286. https://doi.org/10.1016/j.jchromb.2007.07.036.

28. Takai A, Lai D, Mikkelsen L, Abou Hachem M, Shelton D, Motawia MS, Olsen CE, Wang TL, Martin C, Rook F. 2010. Genetic screening identifies cyanogenesis-deficient mutants of Lotus japonicus and reveals enzymatic specificity in hydroxynitrile glucoside metabolism. Plant Cell 22:1605–1619. https://doi.org/10.1105/tpc.109.073502.

29. Scalbert A, Andres-Lacueva C, Anita M, Kroop P, Manach C, Urpi-Sarda M, Wishart D. 2011. Databases on food phytochemicals and their health-promoting effects. J Agric Food Chem 59:4331–4346. https://doi.org/10.1021/jf200591d.

30. Landete JM, Curiel JA, Rodríguez H, de las Rivas B, Muñoz R. 2014. Aryl glycosidases from Lactobacillus plantarum increase antioxidant activity of phenolic compounds. J Funct Foods 7:322–329. https://doi.org/10.1016/j.jff.2014.01.028.

31. Laparra JM, Sanz V. 2010. Interactions of gut microbiota with functional food components and nutraceuticals. Pharmacol Res 61:219–225. https://doi.org/10.1016/j.phrs.2009.11.001.

32. Possemiers S, Rabot S, Espin JC, Bruneau A, Philippe C, González-Sarrias A, Heyerek A, Tomás-Barberán FA, De Keuckeleire D, Verstraete W. 2008. Eucubacterium limosum activates isoxanthohumol from hops (Humulus lupulus L) into the potent phytoestrogen 8-prenylnaringenin in vitro and in rat intestine. J Nutr 138:1310–1316.

33. Carmody RN, Turnbaugh PJ. 2014. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 124:4173–4181. https://doi.org/10.1172/JCI72335.
Metabolism of Plant Glucosides by L. acidophilus

44. Francl AL, Thongaram T, Miller MJ. 2010. The PTS transporters of Lactobacillus gasseri ATCC 33323. BMC Microbiol 10:77. https://doi.org/10.1186/1471-2180-10-77.

45. Deutscher J, Ake FMD, Derkaoui M, Zébré AC, Cao TN, Bourouhi H, Kentache T, Mokhtari A, Milohanic E, Joyet P. 2014. The bacterial phosphoenolpyruvate-carbohydrate phosphotransferase system: regulation by protein phosphorylation and phosphorylation-dependent protein–protein interactions. Microbiol Mol Biol Rev 78:231–256. https://doi.org/10.1128/MMBR.00014-14.

46. Saier MH, Reddy VS, Tsu BV, Ahmed MS, Li C, Moreno-Hagelsieb G. 2016. The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res 44:D372–D379. https://doi.org/10.1093/nar/gkv1103.

47. Manach C, Hubert J, Llorach R, Scalbert A. 2009. The complex links between dietary phytochemicals and human health deciphered by metabolomics. Mol Nutr Food Res 53:1303–1315. https://doi.org/10.1002/mnfr.200900516.

48. Dillard CJ, German JB. 2000. Phytochemicals: nutraceuticals and human health. J Sci Food Agric 80:1744–1756. https://doi.org/10.1002/1097-0022(20000915)80:12<1744::AID-JSFA725>3.0.CO;2-W.

49. Taguer M, Maurice CF. 2016. The complex interplay of diet, xenobiotics, and microbial metabolism in the gut: implications for clinical outcomes. Clin Pharmacol Ther 99:588–599. https://doi.org/10.1002/cpt.366.

50. Maurice CF, Kaiser HI, Turnbaugh PJ. 2013. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152:39–50. https://doi.org/10.1016/j.cell.2012.10.052.

51. Schmid B, Köttler I, Heide L. 2001. Pharmacokinetics of salicin after oral administration of a standardised willow bark extract. Eur J Clin Pharmacol 57:387–391. https://doi.org/10.1007/s0022800100325.

52. Whang WK, Park HS, Ham I, Oh M, Namkoong H, Kim HK, Hwang DW, Hur SY, Kim TE, Park YG, Kim JR, Kim JW. 2005. Natural compounds, fraxin and chemicals structurally related to fraxin protect cells from oxidative stress. Exp Mol Med 37:436–446. https://doi.org/10.1038/sj.emm.54.00554.

53. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistel PJ, Pooasa S, Becker KG, Boss O, Gwinn D, Wang MY, Ramaswamy S, Fishbein KW, Rakitta EG, Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. 1989. Engineering hybrid genes without the use of restriction enzymes—gene-splicing by overlap extension. Gene 77:61–68. https://doi.org/10.1016/0378-1119(89)90354-4.

54. Bang MS, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Kong HK, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. 1997. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220. https://doi.org/10.1126/science.275.5297.218.

55. Smoliga JM, Baur JA, Hausenblas HA. 2011. Resveratrol and health—A comprehensive review of human clinical trials. Mol Nutr Food Res 55:1129–1141. https://doi.org/10.1002/mnfr.201100143.

56. Setchell KDR, Clerici C. 2010. Equol: history, chemistry, and formation. J Nutr 140:1355S–1362S. https://doi.org/10.3945/jnp.110.119776.

57. Decroos K, Vanhemmens S, Cattoir S, Boon N, Verstraete W. 2005. Isolation and characterisation of an equol-producing mixed microbial culture from a human faecal sample and its activity under gastrointestinal conditions. Arch Microbiol 183:45–55. https://doi.org/10.1007/s00203-004-0747-4.

58. Salvetti E, Torrani S, Felis GE. 2012. The genus Lactobacillus: A taxonomic update. Probiotics Antimicrob Proteins 4:217–226. https://doi.org/10.1007/s12602-012-9117-8.

59. Russell WM, Klænhammer TR. 2001. Efficient system for directed integration into the Lactobacillus acidophilus and Lactobacillus gasseri chromosomes via homologous recombination. Appl Environ Microbiol 67:4361–4364. https://doi.org/10.1128/AEM.67.9.4361-4364.2001.

60. Kimmel SA, Roberts RF. 1998. Development of a growth medium suitable for exopolysaccharide production by Lactobacillus delbrueckii ssp. bulgaricus RR. Int J Food Microbiol 40:87–92. https://doi.org/10.1016/S0168-1605(98)00023-3.

61. Duncan SH, Hold GL, Barceniella A, Stewart CS, Flint HJ. 2002. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol 52:1615–1620. https://doi.org/10.1099/ijsem.0.0207713-52-S-1615.

62. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A, Markowitz S, Duran C, Thierer T, Ashdon B, Meintjes P, Drummond A. 2012. Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics 28:1647–1649. https://doi.org/10.1093/bioinformatics/bts199.

63. Goh YJ, Klænhammer TR. 2013. A functional glycoscan biosynthesis pathway in Lactobacillus acidophilus: expression and analysis of the glg operon. Mol Microbiol 89:1187–1200. https://doi.org/10.1111/mmi.12338.

64. Saier MH, Reddy VS, Tamang DG, Västermark A. 2014. The Transporter classification database. Nucleic Acids Res 42:D251–D258. https://doi.org/10.1093/nar/gkt1097.

65. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR. 1989. Engineering hybrid genes without the use of restriction enzymes—gene-splicing by overlap extension. Gene 77:61–68. https://doi.org/10.1016/0378-1119(89)90359-4.

66. Wang YN, Zhao M, Ou YF, Zeng BW, Lou XY, Wang M, Zhao CJ. 2016. Metabolic profile of esculin in rats by ultra high performance liquid chromatography combined with Fourier transform ion cyclotron resonance mass spectrometry. J Chromatogr B Analyst Technol Biomed Life Sci 1020:120–128. https://doi.org/10.1016/j.jchromb.2016.03.027.

67. Kingsford CL, Ayanbule K, Salzberg SL. 2007. Rapid, accurate, computational discovery of Rho-independent transcription terminators illuminates their relationship to DNA uptake. Genome Biol 8:R22. https://doi.org/10.1186/gb-2007-8-2-r22.